Comparative Efficacy of Elotuzumab, Pomalidomide, and Dexamethasone vs Standard Care Triplets in Relapsed/Refractory Multiple Myeloma After at Least One Prior Line of Therapy: A Network Meta-Analysis (IMS 2026) - Sep 11, 2026 - Abstract #PA-108; Pres time: Sep 24, 2026; "Assuming equivalence ( collapsed node s ) between pomalidomide – dexamethasone (Pd) and bortezomib – dexamethasone ( Vd ), and between carfilzomib – dexamethasone ( Kd ) and lenalidomide – dexamethasone (Rd), EPd showed no statistically significant difference in PFS versus any of the eight comparator triplet regimens ; HRs ( 95% CrIs ) ranged from 0.81 ( 0.43 – 1.54 ) versus selinexor – Vd to 1.39 ( 0.69 – 2.85 ) versus daratumumab (D )– Kd , with all CrIs crossing 1. This NMA found no statistically significant differences in PFS between EPd and other approved or guideline-recommended triplet regimens in patients with RRMM with ≥1 prior line of therapy, any prior R exposu re , and no prior anti-CD38 exposure . Results were consistent in the R-refractory sub group across alternative pooled doublet scenarios, supporting EPd as a n appropriate control among SOC options . Ongoing trials including EPd in anti-CD38 – exposed/refractory populations may help further..."
Retrospective data • Hematological Malignancies • Multiple Myeloma
|
|
Katja Weisel1; Sam Keeping2; Yingxin Xu3; Heather Burnett4; Ina Zhang2; Tito Roccia3; Glenn S. Kroog3; Wanning Xu3; Qiufei Ma3; Peter Voorhees5
|